Cytokines and Cognitive Decline in Alzheimer's Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2011 by Poitiers University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Poitiers University Hospital
ClinicalTrials.gov Identifier:
NCT01351142
First received: May 6, 2011
Last updated: May 10, 2011
Last verified: May 2011

May 6, 2011
May 10, 2011
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT01351142 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Cytokines and Cognitive Decline in Alzheimer's Disease
Not Provided

Amyloid plaques and neurofibrillary tangles are the 2 well-known etiopathological hallmarks of Alzheimer's disease (AD). Beside these 2 lesions, inflammation response is described in the brain of patients with AD.

The main objective of our study is to analyse the correlation between the value of plasma cytokines (interleukin 1, 6, TNFα and chemochine Rantes) and the rapidity of the cognitive decline in AD over a 2-year follow-up.

Secondary objectives include:

  • the predictive value of the cytokines on the cognitive decline after 6 months and one year of follow-up., of the patients include 150 patients with AD (MMSE: 16-25)
  • correlation between plasma cytokines levels and expression of the protein kinase PKR (involved in death cell) in blood mononuclear cells.
Not Provided
Interventional
Not Provided
Intervention Model: Single Group Assignment
Alzheimer's Disease
Other: blood test and cognitive tests
Specific cognitive tests are performed at day 1, month 6, one year and 2 years Specific Blood samples tests are performed at inclusion, 1 years and 2 years
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Alzheimer's disease (AD)patients
  • MMSE score: 16-25
  • Written informed consent

Exclusion Criteria:

  • AD patients with specific treatment for AD before inclusion MMSE score under 16 or over 25 at inclusion
  • patients with anti-inflammatory drugs (non steroids or corticosteroids) or immunosuppressive agents
  • Patients with acute disease (infectious disease, rheumatologic disease) or chronic disease (malignancy, infectious, rheumatologic disease) that could interact with plasma cytokines level
  • Patients with a life threatening disease
Both
Not Provided
No
Contact: Marc PACCALIN, Professor, MD, Ph +33 5 49 44 44 27 m.paccalin@chu-poitiers.fr
France
 
NCT01351142
CYTOCOGMA
Not Provided
Not Provided
Poitiers University Hospital
Not Provided
Not Provided
Poitiers University Hospital
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP